ROCKVILLE, Md., Jan. 11, 2021 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq: RGNX) today announced it will present at the
39th Annual J.P. Morgan Healthcare Conference on
Thursday, January 14, 2021 at
11:40 a.m. ET. The conference will be
held in a virtual meeting format.
A webcast of the presentation can be accessed in the Investors
section of REGENXBIO's website at www.regenxbio.com. An
archived replay of the webcast will be available in the Investors
section of REGENXBIO's website for approximately 30 days following
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Investor Relations and Corporate Communications
Eleanor Barisser, 212-600-1902
David Rosen, 212-600-1902
SOURCE REGENXBIO Inc.